Objective: To identify the etiology of new-onset seizure in HIV-infected Zambian adults and identify risk factors for seizure recurrence.Methods: A prospective cohort study enrolling HIV-infected adults with new-onset seizure within 2 weeks of index seizure obtained clinical, laboratory, and neuroimaging data to determine seizure etiology. Participants were followed to identify risk factors for seizure recurrence. Risk factors for mortality were examined as mortality rates were unexpectedly high.Results: Eighty-one patients with CSF for analysis were enrolled and followed for a median of 306 days (interquartile range 61-636). Most (91%) were at WHO stage III/IV and 66 (81%) had a preseizure Karnofsky score $50. Prolonged or multiple seizures occurred in 46 (57%), including 12 (15%) with status epilepticus. Seizure etiologies included CNS opportunistic infections (OI) in 21 (26%), hyponatremia in 23 (28%), and other infections in 8 (10%). OIs included Cryptococcus (17%), JC virus (7%) and 5% each for tuberculosis, cytomegalovirus, and varicella-zoster virus. No etiology could be identified in 16 (20%). Thirty (37%) patients died during follow-up and 20 (25%) had recurrent seizures with survival being the only identifiable risk factor. Seizures are common in the HIV-infected population, often occurring in the setting of advanced stages of immunosuppression.1 New-onset seizure has been reported in up to 11% of HIVinfected individuals, 2,3 but seizure recurrence risk and risks factors for epilepsy development in HIV-infected individuals with new-onset seizure have not been delineated. Most African regions with high HIV prevalence continue to rely largely on older, enzyme-inducing antiepileptic drugs (AEDs) for epilepsy management. Given the potential for drug interactions between enzymeinducing AEDs and combined antiretroviral therapy (cART), their co-usage is not recommended, 4,5 but other seizure treatment options are often limited or nonexistent. 6 Data on the risk of seizure recurrence in HIV-infected people with new-onset seizure are needed to help guide the decision whether or not to initiate AEDs, particularly given the risk of increased drug toxicity